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Background: Heteromeric  glycine receptor / interfaces have never been characterized unambiguously.
Results: This interface, compared with the / interface, is highly sensitive to agonist and experiences distinct conforma-
tional changes upon agonist binding.
Conclusion: The / interface exhibits distinct properties.
Significance: Our investigation directs the / interface-specific drug design and provides a general methodology for
unambiguously characterizing heteromeric proteins interfaces.
The glycine receptor (GlyR) exists either in homomeric  or
heteromeric forms. Its agonists bind at extracellular subunit
interfaces. Unlike subunit interfaces from the homomeric 
GlyR, subunit interfaces from theheteromericGlyRhave not
been characterized unambiguously because of the existence of
multiple types of interface within single receptors. Here, we
report that, by reconstituting/ interfaces in a homomeric
GlyR (ChbaGlyR), we were able to functionally character-
ize the  GlyR / interfaces. We found that the /
interface had ahigher agonist sensitivity than that of the/
interface. This high sensitivity was contributed primarily by
loop A. We also found that the / interface differentially
modulates the agonist properties of glycine and taurine. Using
voltage clamp fluorometry, we found that the conformational
changes induced by glycine binding to the / interface
were different from those induced by glycine binding to the
/ interface in the  GlyR. Moreover, the distinct confor-
mational changes found at the / interface in the
Chba GlyR were also found in the heteromeric  GlyR,
which suggests that theChbaGlyR reconstitutes structural
components and recapitulates functional properties, of the
/ interface in the heteromericGlyR.Our investigation
not only provides structural and functional information about
the GlyR / interface, which could direct GlyR /
interface-specific drug design, but also provides a generalmeth-
odology for unambiguously characterizing properties of specific
protein interfaces from heteromeric proteins.
The Cys-loop ligand-gated ion channels are postsynaptic
neurotransmitter receptors, and include the nicotinic acetyl-
choline receptor (nAChR),2 the 5-hydroxytryptamine type 3
receptor, the type-A -aminobutyric acid receptor (GABAAR),
and the glycine receptor (GlyR) (1–5).Members of this receptor
family exist predominantly as heteromeric pentamers and are
constructed froma group of homologous subunits that varies in
size from five (1–4 and ) for the GlyR to 19 for the GABAAR.
Each pentameric subunit combination exhibits a unique elec-
trophysiological and pharmacological profile. This creates a
wide functional diversity within a given receptor type, which is
essential for optimal nervous system function and also provides
an opportunity for pharmacologists to design treatments for
specific pathophysiological conditions. Ligand-binding sites
are found at subunit interfaces, and the structure, and hence the
functional properties, of these sites are determined by the sub-
units that contribute to the formation of these interfaces. It is
difficult to characterize the functional properties of an individ-
ual ligand-binding site due to the variety of sites that co-exist
within a given heteromeric pentamer.
Each Cys-loop receptor subunit is composed of an N-termi-
nal extracellular domain (ECD), four transmembrane domains,
termed M1–M4, and a large intracellular domain between M3
andM4. The channel pore is lined by M2 domains contributed
by each subunit. Agonist binding to the receptor ECD initiates
a local conformational change that propagates away from the
binding site, ultimately leading to the opening of a gate in the
channel pore (9–14). Each ECD is composed primarily of two
sheets, where  strands are connected by flexible loops. As
noted above, agonist binding sites are located at the ECD sub-
unit interfaces. Loops A, B, and C from the principal () sub-
unit interface and loops D, E and F (and loop G in some cases)
from the complementary () subunit interface form a pocket
that hosts the agonist binding site (6–8), whereas loop 2, the
conserved Cys-loop, and the pre-M1 linker form a transition
zone, which connects the ECD to the transmembrane domain
(7, 9–14). Despite sharing common structural and functional
characteristics, ECD subunit interfaces formed by different
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combinations of subunits do not contribute equally to agonist
binding. For example, in the muscle 2 nAChR, only the
/ and / subunit interfaces have the ability to bind
the agonist, acetylcholine (15). Likewise, the 22 GABAAR
binds its agonist GABA only at the two / interfaces (16–
18). In contrast to the heteromeric nAChR and GABAAR, the
heteromeric23GlyR is thought to bind the agonist glycine at
all available subunit interfaces (19). In addition to forming the
binding site for agonists, the ECD subunit interface also forms
the binding site for modulators of clinical importance. For
example, benzodiazepines bind to the GABAAR at the /
(2, 3, 17), or occasionally at the / ECD subunit interfaces
(20, 21), but not theGABA-binding/ECD subunit inter-
face. To precisely understand the functional properties of Cys-
loop receptors, it is essential to unambiguously characterize
individual subunit interfaces without interference from other
subunit interfaces. However, this generally is not possible using
traditional site-directedmutagenesis strategies as a givenmuta-
tion may interfere with more than one type of interface. For
example, to investigate the properties of the () side of the
/ interface in the 2 nAChR, mutations would be
introduced into the  side, and their effect would be exam-
ined by functional assays such as electrophysiological record-
ing. However, any effect detected in this way might arise
from the mutation occurring at the / rather than
/ interfaces. The traditional methodology cannot dis-
tinguish these two possibilities.
This was the situation before structural information became
available. The past 10 years has seen structures of various Cys-
loop receptors revealed (6, 8, 9, 11). Here, we used this struc-
tural information to reconstitute the / interface of the
heteromeric GlyR in a homomeric GlyR, by building a com-
plex chimera. The chimeric GlyR allowed us to unambiguously
characterize the properties of the / interface by compar-
ing it with the / interface. We found that the /
interface has a higher agonist sensitivity than that of the
/ interface. In addition, the conformational changes that
occur at the / interface upon agonist binding are differ-
ent from those occurring at the / interface. Our investi-
gation not only provides functional and structural information
of theGlyR/ interface, whichwould direct GlyR/
interface-specific drug design, but also provides a general
methodology for unambiguously characterizing properties of
specific protein interfaces from heteromeric proteins.
EXPERIMENTAL PROCEDURES
Mutagenesis and Chimera Construction of GlyR cDNAs—
The human GlyR 1 and  cDNAs were subcloned into the
pcDNA3.1zeo (Invitrogen) or pGEMHE (22) plasmid vectors
for expression in HEK293 cells or Xenopus oocytes, respec-
tively. Site-directed mutagenesis and chimera construction
were performed using the QuikChange (Stratagene, La Jolla,
CA) mutagenesis and multiple-template-based sequential PCR
protocols, respectively.
The multiple-template-based sequential PCR protocol for
chimera construction was developed in our laboratory and
recently has been described in detail elsewhere (23). This pro-
cedure does not require the existence of restriction sites or the
purification of intermediate PCR products and needs only two
or three simple PCRs followed by general subcloning steps.
Most importantly, the chimera join sites are seamless, i.e. no
linker sequence is required, and the success rate for construc-
tion is nearly 100%. The joining sites used in our experiment
were chosen based on two criteria. First, the site, based on the
crystal structure of the acetylcholine binding protein (5),
should be located near the boundary between the two flanking
loops to minimize disturbance on the loop structures. Second,
the pair of residues between which a joining site is formed
should be conserved between the GlyR  and  subunits, if
possible. The joining sites used in our experiment are between
the following pairs of residues:  Ile93-Trp94 and  Leu116-
Trp117 for the N terminus of loop A,  Phe108-His109 and 
Phe131-His132 for the C terminus of loop A and the N terminus
of loop E,  Leu134-Thr135 and  Ile157-Thr158 for the C termi-
nus of loop E and the N terminus of the Cys-loop,  Gln155-
Leu156 and  Gln178-Leu179 for the C terminus of the Cys-loop
and the N terminus of loop B,  Glu172-Gln173 and  Ser195-
Gly196 for the C terminus of loop B and the N terminus of loop
F, Glu192-Lys193 and  Asp215-Ile216 for C terminus of loop F
and the N terminus of the loop C,  Thr208-Cys209 and 
Thr232-Cys233 for the C terminus of loop C and the N terminus
of the pre-M1 linker, and  Gly221-Tyr222 and  Gly245-Phe246
for the C terminus of the pre-M1 linker and the N terminus of
the transmembrane domain (supplemental Fig. 1). The loop 2
transposition was achieved by incorporating either the A52Q
or Q73A mutations, as the loop 2 sequences between the 1
and  subunits are otherwise conserved. To facilitate compar-
ison, residue numbering in chimeric constructs is based on the
respective homologous residue in the 1 subunit.
For the voltage clamp fluorometry (VCF) experiments, the
cysteines equivalent to the1 Cys41 andCys115 weremutated
to alanines to minimize possible background labeling. Neither
mutation affects channel function (24, 25).
HEK293 Cell Culture, Expression, and Electrophysiological
Recording—The agonist EC50 values were determined onGlyRs
expressed in HEK293 cells. Details of the HEK293 cell culture,
GlyR expression, and electrophysiological recording of the
HEK293 cells are described elsewhere (26). Briefly, HEK293
cells were maintained in DMEM supplemented with 10% fetal
bovine serum. Cells were transfected using a calcium phos-
phate precipitation protocol. In addition, the pEGFP-N1 (Clon-
tech) was co-transfected to facilitate the identification of trans-
fected cells. Glycine-induced currents weremeasured using the
whole cell patch clamp configuration. Cells were treated with
external Ringer’s solution and internal CsCl solution (27). Cells
were voltage clamped at40 mV.
Oocyte Preparation, Expression, and VCF Recording—VCF
experiments were performed on GlyRs expressed in Xenopus
oocytes. Details of oocyte preparation, GlyR expression, and
VCF recording are described elsewhere (28, 29). Briefly, the
mMESSAGE mMACHINE kit (Ambion, Austin, TX) was used
to generate capped mRNA. The mRNA was injected into
oocytes of the female Xenopus laevis frog at a dose of 10 ng (10
ng ofWT or chimeric 1 when expressing homomers, and 1 ng
of 1 and 9 ng of  when expressing heteromers) per oocyte.
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After injection, the oocytes were incubated in ND96 solution
(30) for 3–4 days at 18 °C before recording.
Sulfhydryl-reactive reagents, sulforhodamine methanethio-
sulfonate (Toronto Research Chemicals, North York, Ontario,
Canada), 2-((5(6)-tetramethylrhodamine) carboxylamino)-
ethylmethanethiosulfonate (MTS-TAMRA, Toronto Research
Chemicals, North York, Ontario, Canada) and tetramethylrho-
damine-6-maleimide (TMRM, Invitrogen), were used to label
the introduced cysteine residues (sulforhodamine methaneth-
iosulfonate, Q219C; MTS-TAMRA, A52C, Q67C, K203C;
TMRM, R217C or E217C). On the day of recording, the oocytes
were labeledwith 10M sulforhodaminemethanethiosulfonate
for 25 s, MTS-TAMRA (on ice) for 25 s, TMRM (on ice) for 30
min, either in the absence or presence of glycine. The oocytes
were then transferred to the recording chamber and perfused
with ND96 solution. The current was recorded by the two-
electrode voltage clamp configuration, and the recording elec-
trodewas filledwith 3MKCl. Cells were voltage clamped at40
mV. The fluorescence was recorded using the PhotoMax 200
photodiode detection system (DaganCorp.,Minneapolis,MN).
DataAnalysis—Results are expressed asmean S.E. of three
or more independent experiments. The empirical Hill equa-
tion, fitted by a non-linear least squares algorithm (SigmaPlot,
version 11.0, Systat Software, Point Richmond, CA), was used
to calculate the EC50 andHill coefficient (nH) values for glycine-
induced current and fluorescence changes. The agonist bind-
ing/gating energy of each chimeric construct relative to that of
the 1WT GlyR (G) was determined by the formula
G(kJ/mol)  RTln(EC50chi)  RTln (EC50WT). Specifically,
the variance of Gwas calculated by using standard methods
for error propagation (supplemental data). Statistical signifi-
cance was determined using the Student’s t test (SigmaPlot,
version 11.0).
RESULTS
Relative Contributions of Loops A, B, and C to Glycine Sensi-
tivity at/ Interface—Tocompare the glycine sensitivities
of the / and / interfaces, we created three chime-
ric GlyRs by replacing loop A, B, or C in the  GlyR with the
corresponding loop from the  subunit. These chimeras were
named ChLa, ChLb, and ChLc GlyRs, respectively (Fig. 1
and supplemental Fig. 1). Electrophysiological recording dem-
onstrated that the ChLa GlyR (EC50 3.7  0.9 M) was 8.9 
2.2 times more sensitive (p  0.01) to glycine than the  GlyR
(EC50 33 2M) (Fig. 2A and Table 1). The EC50 is a reflection
of the binding and gating abilities of an agonist (31), and there-
fore, the higher glycine sensitivity of the ChLa GlyR implies
that loop A from the / interface contributes more bind-
ing/gating energy than the corresponding loop from the
/ interface. In contrast, the ChLb GlyR (EC50, 69  6
M) demonstrated a glycine sensitivity 2.1  0.2 times lower
(p 0.01) than that of the GlyR (Fig. 2A and Table 1), imply-
ing that loopB from the/ interface contributes less bind-
ing/gating energy than that from the/ interface. To facil-
itate comparison of the relative contribution of each loop to
agonist binding/gating energy, we set the energy level of the 
GlyR at 0. The binding/gating energy levels of other constructs
were then calculated relative to the GlyR (G). The relative
glycine binding/gating energies of loops A, B, and C from the
/ interface were5.4 0.6 (significantly0, p 0.01),
1.8  0.3 (significantly 0, p  0.01) and 0.22  0.32 kJ/mol
(not significantly different from 0, p 0.05) (Fig. 2B and Table
1), respectively.
Interactions between Loops A, B, and C Affect Glycine
Binding/Gating—Previous investigations based on crystal
structures and mutation/modeling of the Cys-loop receptors
have shown that the agonist binds to the ECD subunit interface
through the interaction between specific moieties of agonist
molecules and specific amino acids of loops A, B, C, D, E, and F
(32–34). In such a mode, it has been assumed that each loop
contributes independently to agonist binding/gating energy.
However, when we introduced both loops A and B from the
GlyR  subunit into the  GlyR (ChLaLb GlyR) (Fig. 1), it
FIGURE1.Chimera constructionof theGlyR1and subunits. Sequences
of GlyR 1 and  subunits are in gray and black, respectively. The abbrevia-
tions are as follows: L2, loop2; Ld, loopD; La, loopA; Le, loopE;Cy, Cys-loop; Lb,
loop B; Lf, loop F; Lc, loop C; Pm, pre-M1; TMD, transmembrane domain.
FIGURE 2.Relative contributionsof loopsA, B, andC toglycine sensitivity
at the / interface. A, averaged normalized glycine dose-response
curves for the 1WT (●), ChLa (E), ChLb (), and ChLc () GlyRs. B, the
glycine binding/gating energies contributed by loop A (La), B (Lb), and C (Lc)
from the / interface, relative to the homologous loops in the /
interface of the 1 GlyR (**, p  0.01 using Student’s t test). Note that the
glycine dose-response curve for the1WT is reproduced fromShan et al. (41).
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demonstrated a glycine EC50 value of 30 3 M and a relative
agonist binding/gating energy value of 0.24  0.30 kJ/mol
(Fig. 3A and Table 1). Surprisingly, this energy value was not
simply the addition of the energy values of ChLa and ChLb
GlyRs (Fig. 3A and Table 1). We thus concluded that an ener-
getic interaction existed between loops A and B. The interac-
tion energy was expressed as G (interaction)  G
(ChLaLb GlyR)G (ChLa GlyR)G (ChLb GlyR).
This value was calculated to be 3.4 0.7 kJ/mol between loops
A and B, which was significantly higher than 0 (p 0.01) (Fig.
3D). A positive value of interaction energy implies a negative
cooperation between loops A and B in contributing to agonist
binding/gating. Similar electrophysiological characterizations
and calculationswere also applied to chimericGlyRs contain-
ing both loops A and C (ChLaLc GlyR) (Figs. 1 and 3B), and
both loops B and C (ChLbLc GlyR) (Figs. 1 and 3C), from the
 subunit. The respective interaction energies were 1.8  0.8
kJ/mol (not significantly different from 0, p 0.05) and2.2
0.6 kJ/mol (significantly 0, p  0.05) (Fig. 3D). These results
indicated a positive cooperation exists between loopsB andC in
contributing to glycine binding/gating.
Agonist Sensitivity of / Interface—The ChLaLbLc
GlyRwas constructed by introducing loopsA, B, andC from the
GlyR  subunit together into the GlyR. This homomeric chi-
meric GlyR thus incorporated the () side of the  subunit and
the () side of the  subunit at its agonist-binding pockets,
mimicking those existing at the / interfaces in the het-
eromeric  GlyR. Therefore, we hypothesized that this con-
struct would report the properties of the / interfaces in
the GlyR. This construct demonstrated a glycine EC50 value
of 4.7 0.7 M (Fig. 4C and Table 1).
However, other loops apart from loops A–F, such as loop 2,
the Cys-loop, and the pre-M1 linker also exist in the () side of
the ECD subunit interface. Although these domains do not par-
ticipate in agonist binding, they mediate channel gating (32–
34). To faithfully report the agonist binding/gating properties
of the / interface, we therefore next introduced loop 2,
theCys-loop, and the pre-M1 linker from the subunit into the
ChLaLbLc GlyR (Fig. 1 and Fig. 4, A and B). This construct,
named Chba GlyR, exhibited a glycine sensitivity compa-
rable to theChLaLbLcGlyR (EC50 3.7 0.4M forChba
GlyR versus 4.7  0.7 M for ChLaLbLc GlyR, Fig. 4C and
Table 1). Consistently, a control construct, the ChL2CyPm
GlyR, where only loop 2, the Cys-loop, and the pre-M1 linker
from the  subunit were introduced into the  GlyR, exhibited
a glycine sensitivity comparable with that of the  GlyR
(ChL2CyPm GlyR EC50 54 10 M, Table 1). This implies
that loop 2, the Cys-loop, and the pre-M1 linker from the
/ interface contribute to the gating to an extent similar to
that of the / interface.
Both the Chba and ChLaLbLc GlyRs demonstrated
muchhigher sensitivity toward glycine than theGlyR (EC50
33  2 M, p  0.01, Fig. 4C, and Table 1), implying that the
/ interface might have a higher glycine binding/gating
ability than the / interface. It is worth noting that the
glycine sensitivities of both the ChLaLbLc and Chba
GlyRs were also higher than that of the heteromeric  GlyR
(11 2.4M, both p 0.05) (26). The GlyR agonist binding
sites are supposed to be formed by, at least,/ and/
interfaces (19). The glycine sensitivity of the  GlyR might
TABLE 1
Properties of glycine- and taurine-induced currents of GlyRs recorded in HEK293 cells
Note that partial values for the glycine-induced current of the  GlyR are reproduced from Shan et al. (41).
Constructs
Glycine Taurine
EC50 G nH n EC50 G nH
Imax, Tau/
Imax, Gly n
M kJ/mol M kJ/mol %
 33 2 0 2.1 0.2 4 362 59 0 2.5 0.3 99 0 4
ChLa 3.7 0.9 5.4 0.6 2.8 0.3 4 53 9 4.8 0.6 2.5 0.2 100 0 4
ChLb 69 6 1.8 0.3 2.6 0.2 4 584 164 1.2 0.8 2.2 0.3 99 2 4
ChLc 36 4 0.22 0.32 2.9 0.3 4 720 149 1.7 0.7 1.2 0.1 73 6 4
ChLaLb 30 3 0.24 0.30 2.7 0.1 4 134 23 2.5 0.6 2.7 0.1 100 0 4
ChLaLc 8.4 1.7 3.4 0.5 2.7 0.3 4 220 56 1.2 0.8 1.7 0.3 99 1 4
ChLbLc 31 5 0.15 0.43 2.9 0.3 4 436 126 0.5 0.8 1.7 0.1 78 7 4
ChLaLbLc 4.7 0.7 4.8 0.4 2.2 0.2 4 102 26 3.1 0.7 1.7 0.2 94 2 4
ChL2CyPm 54 10 1.2 0.5 2.8 0.2 4 523 139 0.9 0.7 1.6 0.1 85 6 4
Chba 3.7 0.4 5.4 0.3 1.6 0.4 4 80 13 3.7 0.6 1.0 0.1 100 0 4
FIGURE 3. Interactions between loopsA, B, andC at the/ interface.
A, averaged normalized glycine dose-response curves for the ChLa (E),
ChLb (), and ChLaLb (●) GlyRs. B, averaged normalized glycine dose-
response curves for theChLa (E),ChLc (), andChLaLc (●) GlyRs. C, aver-
aged normalized glycine dose-response curves for the ChLb () and ChLc
() and ChLbLc (●) GlyRs. D, Interaction energy between loops A and B
(La–Lb), loops A and C (La–Lc), and loops B and C (Lb–Lc) (*, p 0.05 and **,
p  0.01 using Student’s t test). The interaction energy is calculated, for
instance between loops A and B, using the formulaG (interaction)G
(ChLaLb GlyR)G (ChLa GlyR)G (ChLb GlyR).
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thus be a mixture of the high sensitivity of the / inter-
faces and the relatively low sensitivity of the / interfaces.
Glycine and Taurine Interact Differently with ECD Loops—
Taurine also is an agonist of the GlyR, with a lower affinity and
efficacy than glycine (35). Taurine has a structure that is slightly
different from that of glycine (Fig. 5A), and therefore, themode
of its interactionwith each binding loop of the/ interface
and the subsequent gating process might be different from that
of glycine. To test this hypothesis, we examined the taurine
EC50 values of all the constructs described above (Table 1). The
relative agonist binding/gating energy was calculated in the
same way as for glycine. After comparing the relative agonist
binding/gating energies between taurine and glycine (Fig. 5B),
we found that loops A and B together from the / inter-
face rendered relatively more binding/gating energy for taurine
than for glycine (G of ChLaLb:2.5 0.6 kJ/mol for tau-
rine versus0.24 0.30 kJ/mol for glycine, p 0.01) (Fig. 5B
and Table 1). In contrast, loops B and C together from the
/ interface rendered relatively less binding/gating energy
for taurine than for glycine (G of ChLbLc, 0.5 0.8 kJ/mol
for taurine versus 0.15  0.43 kJ/mol for glycine; p  0.05)
(Fig. 5B and Table 1). The overall/ interface contributed
a slightly less binding/gating energy to taurine than to glycine
(G of Chba, 3.8  0.6 kJ/mol for taurine versus
5.4 0.3 kJ/mol for glycine; p 0.05) (Fig. 5B and Table 1).
These data suggest that loops at the () side of the /
interface contribute to agonist binding/gating to different
extents for taurine and glycine.
Conformational Changes Induced by Agonist Binding to
/ Interfaces in Chba GlyR—We next sought to
compare conformational changes induced by agonist binding
to / and / interfaces by using the VCF technique.
VCF detects local conformational changes in the vicinity of a
residue that has been covalently labeled with an environmen-
tally sensitive fluorescent dye (36, 37). Rhodamine fluorescent
dyes are usually used because rhodamine fluorescence exhibits
an increase in quantum efficiency as the hydrophobicity of its
environment is increased. Thus, fluorescence intensity reports
a change of hydrophobicity of its immediate microenviron-
ment, which is often caused by local conformational changes.
Previously, we characterized conformational changes upon
agonist binding at the / interface in the homomeric 
GlyR (28, 29). To achieve this, we mutated representative resi-
dues from loops C, D, E, and F, loop 2 and the pre-M1 linker to
cysteine, covalently labeled them with various rhodamine fluo-
rescent dyes and then simultaneouslymeasured ligand-induced
current and fluorescence responses. The labeled receptors
demonstrate changes in fluorescence upon the application of
glycine and taurine (28, 29). These changes in fluorescence
reflected conformational changes experienced at the /
interface in the  GlyR upon agonist binding.
Following the same strategy, we introduced cysteine muta-
tions to several residues at the / interface in the
Chba GlyR, at locations homologous to those we previ-
FIGURE 4. Agonist sensitivity of the / interface. A and B, structural
models of the Chba GlyR. Green and red represent sequences from the
GlyR1 and subunits, respectively.A, side viewsof thepentamer, dimer, and
monomer (from left to right). B, bottom views looking from the intracellular
side of the pentamer, dimer, and monomer (from left to right). (The trans-
membranedomains are truncated in thebottomviews for clarity.)C, averaged
normalized glycine dose-response curves for indicated GlyRs. Note that the
GlyR structuremodel is adapted fromLynagh et al. (40), and the glycine dose-
response curves for the  and  GlyRs are reproduced from Shan et al. (41)
and Shan et al. (26), respectively.
FIGURE 5.Differential relative contributions of loops at the/ inter-
face to glycine and taurine binding/gating energies. A, structural formu-
lae of glycine and taurine. B, relative glycine and taurine binding/gating ener-
gies of indicated constructs (*,p0.05 and **,p0.01using Student’s t test).
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ously examined in the/ interface inGlyRs (28, 29) (Fig.
6A). These cysteinemutantChbaGlyRswere labeledwith
the same dyes used for their respective homologous residues at
the / interface in the  GlyR (28, 29) and subjected to
VCF examination. As shown in Fig. 6B andTable 2, a saturating
concentration of glycine generally induced fluorescence
changes that were in the same direction (i.e. increase or
decrease) as those previouslymeasured at the / interface
in theGlyR (28, 29). The only exceptionwas the 217 residue in
the pre-M1 linker. At the / subunit interface, glycine
application induced a decrease in fluorescence changes in the
TMRM-labeled  E217C GlyR (Fig. 6C and Table 2), implying
that the hydrophobicity was decreased in the vicinity of this
residue upon glycine binding. In contrast, at the / sub-
unit interface, glycine application induced a fluorescence
increase in the TMRM-labeled Chba R217C GlyR, imply-
ing that the hydrophobicity was increased in the vicinity of this
residue upon glycine binding.
We also examined conformational changes of the /
subunit interface upon application of taurine. As shown in Fig.
6B, a saturating concentration of taurine induced fluorescence
changes, if could be detected, in the same direction (i.e. increase
or decrease) as observed at the / interface in the  GlyR
(28, 29). Surprisingly, the labeled 217 residue at the /
interface detected a decrease in fluorescence upon taurine
application, which is opposite to that found when glycine was
applied (Fig. 6C). This is reminiscent of responses found at the
labeledM2–M3 loop residue, L274C, in theGlyR (30). L274C,
when labeled with TMRM and subjected to VCF examination,
demonstrated an increase in fluorescence upon glycine appli-
cation and a decrease in fluorescence upon taurine application.
Our data suggest that different agonists induce distinct confor-
mational changes not only in theM2–M3 domain (residue 274)
but also in the pre-M1 linker (residue 217). Interestingly, both
the M2-M3 domain and pre-M1 linker are components of the
transition zone, which is located physically between the extra-
FIGURE 6. VCF data of selective residues at the / interface. A, residues investigated are mapped onto the structural model of the / interface.
B, current and VCF changes of indicated Chba GlyR constructs, upon glycine and taurine applications. C, current and VCF changes of the 217 (or
homologous residue 241 in the subunit) cysteinemutants of theChba,, andGlyRs, uponglycine and taurine applications. Traces inblack represent
current changes, whereas traces in red represent fluorescence changes. Note that the GlyR structure model is adapted from Lynagh et al. (40).
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cellular agonist binding domain and the transmembrane chan-
nel pore and functionally mediates the agonist binding infor-
mation flow to the channel gate. Therefore, it might be a
common phenomenon that residues in the transition zone
experience distinct conformational changes in response to the
binding of glycine and taurine.
Conformational Changes Induced by Agonist Binding to
/ Interfaces in  GlyR—Because the 217 residue at the
/ interface in the Chba GlyR demonstrated a dis-
tinct VCF pattern from the 217 residue at the / interface
in the  GlyR, we wondered whether this pattern could be
duplicated in the heteromeric  GlyR. We mutated residue
241, which is homologous to residue 217, in the heteromeric
GlyR (WTR241C GlyR) and labeled it with TMRM. This
construct exhibited a fluorescence increase upon glycine appli-
cation and a fluorescence decrease upon taurine application
(Fig. 6C). This is the same pattern as found in the Chba
217CGlyR (Fig. 6C), confirming that the ChbaGlyR reca-
pitulates conformational changes that occur at the /
interface of the heteromeric  GlyR.
DISCUSSION
Universal Strategy to Examine Heteromeric Subunit Interface—
The revelation of crystal structures of various Cys-loop recep-
tors in the past decade has revolutionized research in investi-
gating the structure and function of the Cys-loop receptors.
Here, by exploiting this information, we reconstituted the het-
eromeric GlyR / interface in a homomeric GlyR
(ChbaGlyR). This provides a universal strategy for unam-
biguously examining a heteromeric subunit interface by func-
tional assay. Previously, the agonist sensitivity of the /
and / subunit interfaces of the nAChR were examined
either by expressing or dimers or by expressing22 or
22 pentamers (38, 39). However, this cannot be a universal
strategy for characterizing heteromeric subunit interfaces. For
example, in the  GlyR, where the putative stiochiometry is
23 (19), at least two types of agonist-binding interfaces, the
/ and/, could formwhen both subunits are co-ex-
pressed. Therefore, the strategy used for the nAChR as
described above would not be applicable to the GlyR. However,
the strategy we propose here, i.e. reconstituting a heteromeric
subunit interface in a homomeric receptor, is not only univer-
sally applicable for examining any subunit interface, but is also
suitable for traditional functional assays such as electrophysi-
ological recording, because the final construct still remains as a
functional channel. It should be noted that this methodology is
limited by the availability of a functional homomeric protein,
where the heteromeric interface is to be reconstituted.
GlyR / Subunit Interface Exhibits Distinct Properties
from / Subunit Interface—By examining the Chba
GlyR where the / subunit interface is hosted in a homo-
meric GyR using electrophysiological recording, we deter-
mined its agonist sensitivity. Both glycine and taurine demon-
strated sensitivity at this interface higher than those at the
/ interface (8.9 and 4.5 times for glycine and taurine,
respectively, Figs. 4 and 5 and Table 1). This might explain the
finding that the glycine sensitivity of the GlyR (EC50 11
2 M) (26) is slightly higher than that of the  GlyR (EC50 
33 2 M). It should be noted that the key residues contribut-
ing to agonist binding, which were determined previously (
Glu180/ Glu157,  Lys223/ Lys200,  Tyr225/ Tyr202, 
Thr228/ Thr204,  Tyr231/ Phe207, and  Thr232/ Thr208)
from the side are conserved between the/ and/
subunit interfaces (19, 32). Note that the key residues from
the  side are not discussed here because both / and
/ subunit interfaces share the same  side. Therefore,
the difference in agonist sensitivity must arise from the contri-
bution of other residues that presumably play relatively minor
roles in binding/gating. These residues could presumably
induce alterations in loop structure, which leads to a change in
the binding/gating energies of the conserved key residues.
A detailed functional characterization of the GlyR /
subunit interface indicated that its higher agonist sensitivity is
primarily due to loop A. Loop A from the GlyR / subunit
interface showed 8.9 and 6.8 times higher sensitivity toward
glycine and taurine, respectively, than that from the /
subunit interface. In contrast, both loops B and C had relatively
minor effects on agonist sensitivities (Figs. 2 and 5 andTable 1).
Surprisingly, individual loops did not affect agonist binding/
gating independently. We showed that significant negative
cooperation exists between loops A and B, whereas positive
cooperation exists between loops B and C for contributing to
the agonist binding/gating (Fig. 3). This may not be surprising,
considering that all the loops converge into the agonist-binding
cavity and direct physical interactionmight exist between them
(6–8).
Taken together, the / interface exhibited agonist-
binding/gating properties distinct from those of the /
interface. This must have arisen from different conformations
of the / and / subunit interfaces. This hypothesis
was verified by VCF. The 217 residue ( subunit numbering)
TABLE 2
Properties of glycine- and taurine-induced currents and fluorescences of rhodamine fluorescent dye-labeled GlyRs recorded in oocytes
Constructs Dye
Glycine (30 mM) Taurine (30 mM)
Imax Fmax n Imax Fmax n
A % A %
Chba A52C MTS-TAMRA 1.23 0.18 2.69 0.26 5 0.02 0.003 1.76 0.24 3
ChbaQ67C MTS-TAMRA 2.63 0.22 1.85 0.18 5 0.38 0.09 2.31 0.15 4
Chba K203C MTS-TAMRA 0.33 0.05 1.14 0.01 4 a  3
Chba R217C TMRM 3.10 0.49 1.55 0.41 5 0.04 0.007 0.79 0.11 5
ChbaQ219C MTSR 0.82 0.31 1.48 0.02 4   4
 E217C TMRM 2.17 0.33 1.18 0.12 4 1.88 0.22 1.07 0.15 4
WT  R241C TMRM 4.37 0.27 1.20 0.10 5 3.56 0.19 1.09 0.19 5
a, no signal was detected.
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exhibited fluorescence changes upon glycine application that
were opposite in direction at the / and / subunit
interfaces (Fig. 6), implying distinct dynamic conformational
changes upon agonist binding in the / subunit interface,
compared with the / subunit interface.
Although the / interface exhibits properties distinct
from those of the/ interface for both glycine and taurine,
it does not contribute to both glycine and taurine binding/gat-
ing to the same extent (Fig. 5). This phenomenon was also
reflected in a dynamic mode revealed through a VCF examina-
tion. The 217 residue in the/ interface indicated fluores-
cence changes in opposite directions upon glycine and taurine
applications (Fig. 6). Moreover, this distinct pattern was also
duplicated in the heteromeric GlyR (Fig. 6), which confirms
that the Chba GlyR reconstitutes structural components
and recapitulates functional properties, of the/ interface
in the heteromeric  GlyR.
Use of Heteromeric Subunit Interface Reconstituted in Homo-
meric Protein—Ahomomeric protein hosting heteromeric sub-
unit interfaces would be useful for unambiguously characteriz-
ing heteromeric subunit interfaces, as described above. This
characterization would provide information for interface-spe-
cific drug design.
Currently, one of the major problems in clinical drugs is lack
of specificity, partially because most proteins mediate many
functions. For example, GABAARs are distributed widely
throughout the central nervous system and involved in many
neural functions. A GABAAR-targeting drug that attempts to
correct one neural function could interfere with many other
neural functions as well. Fortunately, GABAARs are con-
structed from a total of 19 subunits, and certain combinations
have a limited distribution and are thus likely to have a
restricted functional role (2, 3). Currently GABAAR subtype-
specific drugs are being pursued. Although this strategy would
render specificity to certain extent, itmight not be enough. (For
example, the GABAAR1 subtype universally distributes in the
central nervous system.) As one subtype, by combining with
various other subtypes, could form many types of interfaces,
interface-specific drugs would potentially render more speci-
ficity. The system we report here, i.e. reconstituting a hetero-
meric subunit interface in a homomeric protein, is an ideal tool
for screening for subunit interface-specific drugs.
These subunit interface-specific drugs would be useful not
only for clinical medicine, but also for basic physiological
research. For example, although subtypes of Cys-loop receptors
existing in certain brain regions can be readily identified cur-
rently, the exact stoichiometry of native receptors cannot. It
should be noted that native receptors only exist in few
among many possible combinations of available subtypes
(1–5). Therefore, the exact stoichiometry of native receptors
must be determined experimentally. Subunit interface-spe-
cific drugs can be used as tools to detect whether given sub-
unit interfaces exist and in consequence to determine the
overall stoichiometry.
In addition, the homomeric protein hosting a heteromeric
subunit interface could also be used for raising subunit inter-
face-specific antibodies. Such antibodies could subsequently be
used to detect not only the existence, but also the distribution,
of certain subunit interface-containing proteins. This informa-
tion would provide a precise morphological, physiological, and
pharmacological profile for certain brain areas and eventually
contribute to the design of drugs with high specificity.
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